Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Download All

Gain perspectives on strategies for optimizing use of CDK4/6 and PI3K inhibitors for HR+/HER2- breast cancer, including discussion on effective patient education about these targeted oral therapies! Learn from the experts with downloadable slides, commentaries, podcast, on-demand Webcast, and an Interactive Decision Support Tool providing personalized management recommendations for adverse events associated with CDK4/6 and PI3K inhibitors. Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Matthew P. Goetz, MD
Sara Hurvitz, MD, FACP
Joyce O'Shaughnessy, MD
Laura M. Spring, MD

ClinicalThought

Faculty review recent clinical trial data and provide their insights on the use of CDK4/6 inhibitors and PI3K inhibitors for HR+/HER2- breast cancer.

Matthew P. Goetz, MD Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: March 23, 2021

Hear expert perspective from Laura M. Spring, MD, on how she will integrate adjuvant abemaciclib into clinical practice.

Laura M. Spring, MD Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue